Pomaglumetad methionil

Drug Profile

Pomaglumetad methionil

Alternative Names: DB103; LY 2140023; LY 404039 prodrug; LY2140023 monohydrate; mGlu 2/3; mGlu2/3 pro II

Latest Information Update: 25 Mar 2017

Price : $50

At a glance

  • Originator Eli Lilly
  • Developer Denovo Biopharma; Eli Lilly; New York University School of Medicine
  • Class Amides; Antipsychotics; Carboxylic acids; Heterocyclic bicyclo compounds; Small molecules
  • Mechanism of Action Metabotropic glutamate receptor 2 agonists; Metabotropic glutamate receptor 3 agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Post-traumatic stress disorders; Schizophrenia

Most Recent Events

  • 20 Jul 2015 Phase-I clinical trials in Schizophrenia in USA (PO)
  • 03 Mar 2015 Pomaglumetad methionil licensed to Denovo Biopharma worldwide
  • 30 Aug 2012 Discontinued - Phase-II for Schizophrenia in Argentina (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top